New shot aims to stop dangerous pregnancy condition before it starts
NCT ID NCT07384936
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests an injection called topefilgrastim in 100 pregnant women at high risk for preeclampsia, a serious condition that can harm both mother and baby. Participants are split into two dose groups or a control group to see if the drug can lower the chance of developing preeclampsia. The main goal is to measure changes in key blood markers linked to the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PREECLAMPSIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Lanzhou University Second Hospital
Lanzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a placental protein unlock the mystery of preeclampsia?
- Tiny particles in the blood may warn of dangerous pregnancy high blood pressure
- Vitamin d may cut risk of repeat preeclampsia in High-Risk pregnancies
- Depression drug may mend blood vessels damaged by preeclampsia
- Postpartum blood pressure control may stop preeclampsia from leading to lifelong hypertension
- Genetic clues to severe preeclampsia could transform early detection